Patents by Inventor Mark Llewellyn Lewis

Mark Llewellyn Lewis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinazolinone compounds useful in therapy
    Patent number: 6936619
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, wherein R1 represents C1-4 alkyl; R2 represents halo, C1-4 alkyl, C3-6 cycloalkyl, C3-6 cycloalkyloxy, —SO2(C1-4 alkyl), optionally substituted C1-4 alkyloxy, Het or —OHet; R3 represents a bicyclic group of the formula ?wherein X and Y are selected from C and N, provided that at least one is C; Ring A together with X and Y represents a 5- or 6-membered aromatic ring containing 0, 1, 2 or 3 nitrogen atoms in the ring; n is), 1 or 2 L represents a direct link, C1-4 alkylene or C1-4 alkoxyalkylene; R4 represents H, —NR5R6, C3-6 cycloalkyl, —OR7, Het1 or Het4; R5 and R6 are independently selected from H, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-4 alkylene, —SO2(C1-4 alkyl) and optionally substituted C1-4 alkyl R7 is selected from H, C1-4 alkyl, C1-4 alkoxyalkyl, C3-6cycloalkyl, Het2 and C1-4alkyl-Het3; R8 is H or C1-4 alkyl; Het, Het1, Het2 and Het3 independently represent an optionally substituted 4 to 7 membered saturat
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: August 30, 2005
    Assignee: Pfizer, Inc.
    Inventors: Julian Blagg, Michael Jonathan Fray, Mark Llewellyn Lewis, John Paul Mathias, Mark Henryk Stefaniak, Alan Stobie
  • Oxytocin inhibitors
    Patent number: 6914160
    Abstract: This invention relates to compounds of formula (I)
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: July 5, 2005
    Assignee: Pfizer Inc
    Inventors: Duncan Robert Armour, Andrew Simon Bell, Paul John Edwards, David Ellis, David Hepworth, Mark Llewellyn Lewis, Christopher Ronald Smith
  • Compounds useful in therapy
    Publication number: 20040029859
    Abstract: Compounds of formula (I): 1
    Type: Application
    Filed: March 12, 2003
    Publication date: February 12, 2004
    Applicant: Pfizer Inc.
    Inventors: Julian Blagg, Michael Jonathan Fray, Mark Llewellyn Lewis, John Paul Mathias, Mark Henryk Stefaniak, Alan Stobie
  • Metalloprotease inhibitors
    Patent number: 6511993
    Abstract: Compounds of formula (I) and pharmaceutically-acceptable derivatives thereof, are matrix metalloprotease inhibitors, useful in treatment of conditions mediated by matrix metalloproteases, such as chronic dermal ulcers.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: January 28, 2003
    Inventors: Kevin Neil Dack, Michael Jonathan Fray, Gavin Alistair Whitlock, Mark Llewellyn Lewis, Nicholas Murray Thomson